Skip to main content
Log in

CJ 11974

  • Section 1: Antiemetics in Oncology
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Obach RS, Reed AE. Cross-species correlation of in vitro intrinsic clearance and in vivo clearance for CJ-11,974: considerations of the importance of non-specific binding phenomena, interspecies differences in K(M) values, and activemetabolite formation. 6th European International Society for the Study of Xenobiotics Meeting; 1997 Jun 30-Jul 3; Gothenburg, 213

    Google Scholar 

  2. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999 Jan; 17: 338–43

    PubMed  CAS  Google Scholar 

  3. Hesketh PJ. Studies on new antiemetic drugs [letter, reply]. J Clin Oncol 1999 Jun; 17: 1961–2

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

CJ 11974. Drugs R&D 2, 241–242 (1999). https://doi.org/10.2165/00126839-199902040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902040-00004

Keywords

Navigation